# Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

> **NCT06433947** · PHASE1 · RECRUITING · sponsor: **Opna Bio LLC** · enrollment: 130 (estimated)

## Conditions studied

- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** OPN-6602
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06433947
- **Lead sponsor:** Opna Bio LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433947, "Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06433947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*